A microsatellite polymorphism in the heme oxygenase‐1 gene promoter is associated with risk for melanoma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Heme oxygenase‐1 (HO‐1) has been demonstrated to play an important role in the regulation of signaling systems, which are involved in the control of cell cycle progression and apoptosis. Recently, a (GT)n dinucleotide repeat polymorphism in the HO‐1 promoter was shown to modulate HO‐1 gene expression. Short (<25 GT) repeats are associated with an increased HO‐1 upregulation after stimulation than are longer repeats. Malignant melanoma (MM) is the most serious cutaneous malignancy with high tendency to aggressive growth and resistance to apoptosis. Therefore, we sought to study the influence of this polymorphism on the progression of MM. We determined the HO‐1 promoter genotype in 152 patients with MM and 398 healthy controls and studied their association in regard to susceptibility to MM, Breslow thickness and disease‐free survival. In our study, the homozygous short allele with <25 (GT)n repeats (S/S) was found more frequently in the melanoma group compared to the healthy control population (21 and 12%, respectively). The calculated risk for acquiring primary MM in S/S carriers was 2‐fold higher compared to those with L‐allele types (95% confidence interval: 1.2–2.4, p = 0.03). Additionally, the S/S genotype was significantly associated with primary tumors with deeper Breslow thickness compared to L‐allele (>25 repeats) carriers (mean Breslow thickness: 4.0 ± 2.9 mm versus 3.1 ± 1.7 mm, p = 0.03). These data suggest that HO‐1 might render a higher risk for MM in S/S genotype individuals and could represent an important candidate gene in the pathogenesis and growth of malignant melanoma. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707 · cited 1×
“Increased expression of endogenous stress proteins, including heme oxygenase (HO), is part of the physiologic response to oxidative stress to prevent cell damage.(1) Originally, HO was identified as”
Background
Cited by
Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2223-0 · Cited by 2,632
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
“, patients with low (GT)n repeat genotypes for HO-1 are at risk for drug resistance (Okamoto et al., 2006).”
InfluentialHeme Oxygenase-1 in Tumors: Is It a False Friend?
Jozkowicz, A., Was, H., & Dulak, J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1659 · Cited by 382
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Sheu, C.-C., Zhai, R., Wang, Z., Gong, M. N., Tejera, P., Chen, F., Su, L., Thompson, B. T., & Christiani, D. C. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1504-6 · Cited by 60
Metadata
- Authors
- Okamoto, I., Krögler, J., Endler, G., Kaufmann, S., Mustafa, S., Exner, M., Mannhalter, C., Wagner, O., & Pehamberger, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-04-04
- Volume
- 119
- Issue
- 6
- Pages
- 1312-1315
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2087044010
- Cited by
- 59
- References
- 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.